MXPA02001813A - Hidroxialcanoilaminolactamas y estructuras relacionas como inhibidores de la produccion de la proteina abeta. - Google Patents
Hidroxialcanoilaminolactamas y estructuras relacionas como inhibidores de la produccion de la proteina abeta.Info
- Publication number
- MXPA02001813A MXPA02001813A MXPA02001813A MXPA02001813A MXPA02001813A MX PA02001813 A MXPA02001813 A MX PA02001813A MX PA02001813 A MXPA02001813 A MX PA02001813A MX PA02001813 A MXPA02001813 A MX PA02001813A MX PA02001813 A MXPA02001813 A MX PA02001813A
- Authority
- MX
- Mexico
- Prior art keywords
- aminolactams
- hydroxyalkanoyl
- inhibitors
- protein production
- related structures
- Prior art date
Links
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 abstract 1
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 abstract 1
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 abstract 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 abstract 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000003951 lactams Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Esta invencion se relaciona con lactamas novedosas que tienen la formula (I), con sus composiciones farmaceuticas y con sus metodos de uso. Estos compuestos novedosos inhiben el procesamiento de la proteina precursora amiloidea y, mas especificamente, inhiben la produccion de A(Beta)-peptido, actuando de ese modo para prevenir la formacion de depositos neurologicos de la proteina amiloidea. Mas particularmente, la presente invencion se relaciona con el tratamiento de trastornos neurologicos relacionados con la produccion de ¦-amiloidea tal como la enfermedad de Alzheimer y el Sindrome de Down.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15351199P | 1999-09-13 | 1999-09-13 | |
| US22438800P | 2000-08-09 | 2000-08-09 | |
| PCT/US2000/024967 WO2001019797A2 (en) | 1999-09-13 | 2000-09-13 | HYDROXYALKANOYL AMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF Aβ PROTEIN PRODUCTION |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA02001813A true MXPA02001813A (es) | 2004-03-19 |
Family
ID=26850619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA02001813A MXPA02001813A (es) | 1999-09-13 | 2000-09-13 | Hidroxialcanoilaminolactamas y estructuras relacionas como inhibidores de la produccion de la proteina abeta. |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1212306A2 (es) |
| JP (1) | JP2003509411A (es) |
| CN (1) | CN1399634A (es) |
| AU (1) | AU783914B2 (es) |
| BR (1) | BR0014269A (es) |
| CA (1) | CA2377221A1 (es) |
| IL (1) | IL147774A0 (es) |
| MX (1) | MXPA02001813A (es) |
| WO (1) | WO2001019797A2 (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6960576B2 (en) | 1999-09-13 | 2005-11-01 | Bristol-Myers Squibb Pharma Company | Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production |
| EP1265849B1 (en) | 2000-03-23 | 2006-10-25 | Elan Pharmaceuticals, Inc. | Compounds and methods to treat alzheimer's disease |
| JP2004508289A (ja) | 2000-04-03 | 2004-03-18 | デュポン ファーマシューティカルズ カンパニー | Ａβタンパク質産生の阻害剤としての環状ラクタム |
| CA2404273A1 (en) * | 2000-04-11 | 2001-10-18 | Bristol-Myers Squibb Pharma Company | Substituted lactams as inhibitors of a.beta. protein production |
| US6878363B2 (en) | 2000-05-17 | 2005-04-12 | Bristol-Myers Squibb Pharma Company | Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging |
| GB0012671D0 (en) | 2000-05-24 | 2000-07-19 | Merck Sharp & Dohme | Therapeutic agents |
| WO2001092235A1 (en) | 2000-06-01 | 2001-12-06 | Bristol-Myers Squibb Pharma Company | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Aβ PROTEIN PRODUCTION |
| CA2410972A1 (en) | 2000-06-30 | 2002-01-10 | Elan Pharmaceuticals, Inc. | Compounds to treat alzheimer's disease |
| EP1666452A2 (en) | 2000-06-30 | 2006-06-07 | Elan Pharmaceuticals, Inc. | Compounds to treat Alzheimer's disease |
| US6846813B2 (en) | 2000-06-30 | 2005-01-25 | Pharmacia & Upjohn Company | Compounds to treat alzheimer's disease |
| PE20020276A1 (es) | 2000-06-30 | 2002-04-06 | Elan Pharm Inc | COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER |
| BR0210721A (pt) | 2001-06-27 | 2004-07-20 | Elan Pharm Inc | Composto, sal ou éster farmaceuticamente aceitável, método para fabricar um composto, e, método para tratar um paciente que tem, ou para evitar que o paciente adquira uma doença ou condição |
| EP1466898A4 (en) * | 2001-12-27 | 2005-12-07 | Daiichi Seiyaku Co | INHIBITORS OF THE PRODUCTION / SEPARATION OF BETA-AMYLOIDS PROTEINS |
| WO2003094854A2 (en) | 2002-05-07 | 2003-11-20 | Elan Pharmaceuticals, Inc. | Succinoyl aminopyrazoles and related compounds |
| TW200502221A (en) * | 2002-10-03 | 2005-01-16 | Astrazeneca Ab | Novel lactams and uses thereof |
| EP1633350B1 (en) | 2003-06-05 | 2012-10-03 | Elan Pharmaceuticals, Inc. | Acylated amino acid amidyl pyrazoles and related compounds |
| CA2676715A1 (en) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
| EA017249B8 (ru) | 2007-05-10 | 2013-01-30 | Олбани Молекьюлар Рисерч, Инк. | Арил- и гетероарилзамещенные тетрагидробензо-1,4-диазепины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина |
| DK2222636T3 (da) | 2007-12-21 | 2013-06-03 | Ligand Pharm Inc | Selektive androgenreceptormodulatorer (SARMS) og anvendelser deraf |
| EP2291181B9 (en) | 2008-04-18 | 2013-09-11 | University College Dublin National University Of Ireland, Dublin | Captodiamine for the treatment of depression symptoms |
| WO2015108988A2 (en) | 2014-01-17 | 2015-07-23 | Ligand Pharmaceuticals, Inc. | Methods and compositions for modulating hormone levels |
| CN114096522A (zh) | 2019-04-19 | 2022-02-25 | 利亘制药公司 | 化合物的晶型和制备化合物的晶型的方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666829A (en) | 1985-05-15 | 1987-05-19 | University Of California | Polypeptide marker for Alzheimer's disease and its use for diagnosis |
| CA2272065A1 (en) * | 1996-11-22 | 1998-05-28 | Thomas E. Mabry | N-(aryl/heteroaryl/alkylacetyl) amino acid amides, pharmaceutical compositions comprising same, and methods for inhibiting .beta.-amyloid peptide release and/or its synthesis by use of such compounds |
| AU749658C (en) | 1996-12-23 | 2004-04-29 | Elan Pharmaceuticals, Inc. | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds |
| CA2307221A1 (en) * | 1997-12-22 | 1999-07-01 | Elan Pharmaceuticals, Inc. | Polycyclic .alpha.-amino-e-caprolactams and related compounds |
| JP2002518451A (ja) | 1998-06-22 | 2002-06-25 | エラン ファーマシューティカルズ，インコーポレイテッド | 環状アミノ酸化合物およびその医薬組成物、並びにそれら化合物を用いたβ−アミロイドペプチドの放出および／またはその合成を阻害する方法 |
| HRP990246A2 (en) | 1998-08-07 | 2000-06-30 | Du Pont Pharm Co | Succinoylamino benzodiazepines as inhibitors of a beta protein production |
| AU778005B2 (en) | 1998-12-24 | 2004-11-11 | Bristol-Myers Squibb Pharma Company | Succinoylamino benzodiazepines as inhibitors of Abeta protein production |
-
2000
- 2000-09-13 MX MXPA02001813A patent/MXPA02001813A/es unknown
- 2000-09-13 AU AU74797/00A patent/AU783914B2/en not_active Ceased
- 2000-09-13 WO PCT/US2000/024967 patent/WO2001019797A2/en not_active Ceased
- 2000-09-13 JP JP2001523377A patent/JP2003509411A/ja active Pending
- 2000-09-13 EP EP00963374A patent/EP1212306A2/en not_active Withdrawn
- 2000-09-13 CN CN00812784A patent/CN1399634A/zh active Pending
- 2000-09-13 BR BR0014269-7A patent/BR0014269A/pt not_active Application Discontinuation
- 2000-09-13 CA CA002377221A patent/CA2377221A1/en not_active Abandoned
- 2000-09-13 IL IL14777400A patent/IL147774A0/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU7479700A (en) | 2001-04-17 |
| CA2377221A1 (en) | 2001-03-22 |
| WO2001019797A2 (en) | 2001-03-22 |
| EP1212306A2 (en) | 2002-06-12 |
| WO2001019797A3 (en) | 2002-04-11 |
| BR0014269A (pt) | 2002-07-02 |
| IL147774A0 (en) | 2002-08-14 |
| CN1399634A (zh) | 2003-02-26 |
| JP2003509411A (ja) | 2003-03-11 |
| AU783914B2 (en) | 2005-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA02001813A (es) | Hidroxialcanoilaminolactamas y estructuras relacionas como inhibidores de la produccion de la proteina abeta. | |
| CA2379445A1 (en) | Lactams substituted by cyclic succinates as inhibitors of a.beta. protein production | |
| WO2000038618A3 (en) | SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF Aβ PROTEIN PRODUCTION | |
| WO2001060826A3 (en) | SUCCINOYLAMINO CARBOCYCLES AND HETEROCYCLES AS INHIBITORS OF Aβ PROTEIN PRODUCTION | |
| TR200100377T2 (tr) | Aß Protein üretimi inhibitörleri olarak sukinoilamino laktamlar. | |
| WO2003027068A3 (en) | Substituted amines for the treatment of neurological disorders | |
| TW200502221A (en) | Novel lactams and uses thereof | |
| TW200512195A (en) | Benzamide 2-hydroxy-3-diaminoalkanes | |
| MXPA04003245A (es) | Hidroxipropilaminas. | |
| TW200420550A (en) | Thiazole compounds for the treatment of neurodegenerative disorders | |
| MXPA04000328A (es) | Derivados de alfa-hidroxiamida estatina para tratamiento de enfermedad de alzheimer. | |
| WO2004022523A3 (en) | 1, 3-diamino-2-hydroxypropane prodrug derivatives | |
| NO961326L (no) | Inhibitorer av -amyloidproteinproduksjon | |
| TNSN04017A1 (en) | N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds | |
| TW200505828A (en) | Substituted ureas and carbamates useful in the treatment of alzheimer's disease | |
| MXPA04000338A (es) | Diamindioles para tratamiento de enfermedad de alzheimer. | |
| TW200505418A (en) | Phenacyl 2-hydroxy-3-diaminoalkanes | |
| CA2501799A1 (en) | Pyrazole compounds for treatment of neurodegenerative disorders | |
| MXPA03011521A (es) | Aminadioles para tratamiento de enfermedad de alzheimer. | |
| MXPA03011954A (es) | Nuevos derivados de acido sulfonico. | |
| MXPA03011466A (es) | Macrociclos utiles en tratamiento de enfermedades de alzheimer. | |
| BG104983A (en) | Aryl fused azapolycyclic compounds | |
| WO2006026204A3 (en) | Novel gamma-lactams as beta-secretase inhibitors | |
| MXPA03011502A (es) | Aminoalcoholes sustituidos utiles en tratamiento de enfermedad de alzheimer. | |
| TW200504036A (en) | Novel lactams and uses thereof |